ISSN: 2329-9053

Journal of Molecular Pharmaceutics & Organic Process Research
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Preliminary Report on Management of HIV/AIDS-Associated Opportunistic Skin Infections with PhytodermaTM, a Natural Myco-Based Cream

Yongabi KA1*, AdoteyG2, Chia PN3 and Tiagueu YT4
1Tropical Infectious Diseases and public Health Engineering Research Group (TIDPHERG), Cameroon
2Department of Science Laboratory Technology, Accra Polytechnic, Ghana
3Faculty of Medicine and Health Sciences, Catholic University, Cameroon
4Computer Science Department, Georgia State University, Atlanta, GA, USA
Corresponding Author : Yongabi KA
Tropical Infectious Diseases and public Health
Engineering Research Group (TIDPHERG) Cameroon
Tel: +237-75266162;
E-mail: yongabika@yahoo.com
Received October 25, 2014; Accepted November 13, 2014; Published November 20, 2014
Citation: Yongabi KA, Adotey G, Chia PN, Tiagueu YT (2014) Preliminary Report on Management of HIV/AIDS-Associated Opportunistic Skin Infections with PhytodermaTM, a Natural Myco-Based Cream. J Mol Pharm Org Process Res 2:122. doi: 10.4172/2329-9053.1000122
Copyright: © 2014 Yongabi KA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Abstract

Despite the introduction of Highly Active Antiretroviral Therapy (HAART), opportunistic skin diseases continue to be prevalent and persistent in human immunodeficiency virus-infected individuals. Patients in this study were already receiving antiretroviral therapy for more than 2 years presented clinically with skin malaise previously treated unsuccessfully with conventional antifungal and chemotherapeutic agents. An exit pool system where patients consented to be involved in the study was applied. One hundred (100) out of five hundred and thirty (530) HIV/AIDS patients screened, representing 18.7%, were found with cutaneous infectious fungal infections. Of the 100 HIV/AIDS infected patients with cutaneous infectious fungal infections; Tinea pedis and Tinea unguium had prevalence rate of 60%, Tinea capitis 25%, Tinea corporis 15% respectively. Twenty (20) of the patients in the study had dark/ash color skin depigmentations with swollen hard knobs identified as Kaposi sarcoma Continuous culture of scrapings from the skin, head scalp, finger and toe nails from HIV/AIDS infected patients on malt extract, sabaraud dextrose agars in triplicates as well as KOH microscopy revealed the presence of Trichophyton rubrum, Trichophyton Mentagraphyte, Candida albicans and Microsporium spp. Bulk Methanol and water extracts of Ganoderma lucidum sporophore and whole mushroom fruit of Termitomyces titanicus in a 100% concentration inhibited mycelia growth of all the tests fungi in vitro as compared to growth of mycelium on methanol and water control plates with ketoconazole 200 mg/ ml (undiluted). Crude methanol and water extracts of Ganoderma lucidum and Termitomyces titanicus significantly, in vitro, exhibited inhibition against mycelia spread of Trichophyton rubrum, Trichophton mentagrophytes, Microsporium spp in 4 weeks. The methanol and water crude extracts were formulated into petroleum base cream named PhytodermTM. Phytochemical analyses of extracts from Ganoderma and Termitomyces indicated flavonnoids, saponins, carbohydrates and cardiac Glycosides. The cream administered to 100 patients with 95% efficacy for all skin infections including herpes and Kaposi sarcoma.

Keywords

Top